Recurrence of medulloblastoma appears after 30% to 40% of the surgeries. Different from primary medulloblastoma, in which five-year survival rate is 50%, the survival time of relapses much shorter and only 20% of the patients manage to survive a year. There is a logical need for additional methods of treatment of recurrent medulloblastomas. The aim of the study is to determine the effects of intracavitary and long-term subcutaneous application of Sandostatin (octreotide) on the recurrent medulloblastomas. METHODS: Fourteen children aged 4 to 9 years, in which, despite of craniospinal irradiation and chemotherapy came to a recurrence of medulloblastoma during the first 6 months after the surgery, were treated subcutaneously with Sandostatin (octreotide) in a longer period of time. Cerebellar medulloblastomas with a diameter bigger than 20 mm and spinal over 10 mm were removed operatively and octreotide with Beriplast was applied intracavitary. RESULTS: Magnetic resonance of cranioaxis shows that the application of octreotide has caused the disappearance of spinal drop metastases in all 7 patients and the cerebellar metastases smaller than 5 mm in all 4 patients. Subcutaneous application of octreotide combined with intracavitary expresses an antitumoral effect in 2/3 of the relapses. The application of octreotide results with a transformation of ChangÕs stage M0 into M1 in 71.43% of the patients. CONCLUSION: In the case of in loco or metastatic recurrence of medulloblastomas, intracavitarily and subcutaneously applied octreotide results with a regression of the tumor in a 3 year time within 2/3 of the treated patients.
INTRODUCTION
M edulloblastoma is the most frequent embryonic tumor of the central nervous system (CNS), which appears before the 10th year of life in 75% of the cases, and twice more often in boys (1) . Recurrence of medulloblastoma appears in 30%-40% of the operated patients, most frequently on the position of the previous surgery. A medulloblastoma can reach the spinal cord or other parts of the CNS by the dissemination of the cerebrospinal liquid, while the disseminations out of CNS are very rare. Medical response to a recurrence is a new surgery and an aggressive irradiation and cytostatic therapy on the complete cranioaxis. Certain number of children does not manage to stand the complete therapy, and those who do stand it, have severe problems, especially in neurocognitive functions, concentration, and intelligence (2) (3) (4) (5) . Different from primary medulloblastoma, in which fiveyear survival rate is 50%, the survival time of recurrence is much shorter, and only 20% of the patients manage to survive a year. There is a logical need for additional methods of treatment of recurrent medulloblastomas. Certain peptidomemethichs such as synthetic somatostatin (octreotide) can reduce the level of intracellular cAMP for more than 70% by direct activation of specific receptors on the tumor cells. They can also increase the activity of potassium (K) pump through triggering hyperpolarization of the cell membrane, disabling the potassium to enter the cytosol, what blocks numerous enzymatic systems and lead the cell into apoptosis (6) . Adding the already known indirect antitumor mechanism of octreotide based on the suppression of neovascularisation and lower secreting of growth factors (growth factor, secretin, gastrin...) which are used by the tumor for its growth, initiates the idea of testing octreotide in the therapy of incompletely resected medulloblastomas or their metastases.
The aim of the study was to determine the effects of intracavitary and long-term subcutaneous application of Sandostatin on medulloblastoma recurrences and metastases, from the aspect of influence on tumor growth or involution. The task was also to evident eventual difference in effects, depending on the method of octreotide application.
PATIENTS AND METHODS
The study observes 14 patients (9 boys and 5 girls), aged 4 to 9 years (average 6), who 
RESULTS
ChangÕs ÓM stageÓ has shown in 14 recurrences of medulloblastoma: M4 in 7 (50%), M3 in 4 (28.60%) and M2 in 3 (21.40%) patients (Table 1) Table 1 . Effects of the treatment of recurrent medulloblastomas with intracavitary and subcutaneous application of octreotide During a 3-year monitoring period there was only one death, and it was recorded in the 27th month since the recurrence was evidenced, in a nine-year old boy with a cerebellar recurrence and a thoracic metastasis larger than 5 mm, which did not fulfill the conditions for intracavitary application of octreotide.
Intracavitary application of octreotide in one patient was followed by signs of local obstruction of the circulation of cerebrospinal fluid, for that reason a ventriculoperitoneal shunt was installed. No local intolerant reactions or significant gastrointestinal problems were recorded during the subcutaneous application of octreotide.
DISCUSSION
It is an up-to-date doctrine to treat recurrent medulloblastomas with an aggressive oncological therapy. High-dose chemotherapy with the accompanied autologous transplantation of stem cells offers encouraging results in the treatment of recurrent medulloblastomas (7, 8) .
Intraoperative application of MR can contribute to a more complete resection of the tumor. MR of brain in a patient with a cerebellar medulloblastoma recurrence WHO gr. IV and medulloblastoma metastases in the brain stem: A) Before the surgery, a big cerebellar medulloblastoma with a necrotic zone (thick arrow) and two smaller metastases (narrow arrows) are visible. B) Three months after removing the recurrence and an intracavitary application of octreotide, the mass of the medulloblastoma in the tumor cavity (thick arrow) is smaller, there is one metastasis less in the brain stem, and another one is reduced. C) 6 months after the surgery and the octreotide treatment, there are no remaining of medulloblastoma. D) 2 years after the surgery and the octreotide treatment, there are still no signs of relapse Figure 3 . MR of the cranioaxis 16 months after the cerebellar medulloblastoma surgery, and 6 moths after a cervical metastasis surgery: A) cervical recurrence over 5 mm (thick arrow) and a satellite drop metastasis (narrow arrow) before intracavitary application of octreotide; B) 3 months since the beginning of the octreotide treatment, there is no longer a cervical drop metastasis, and the cervical recurrence is smaller; C) 6 months since the beginning of the octreotide application the cervical recurrence has totally involuted Further studies involving a bigger number of medulloblastomas in which the results of octreotide application could be correlated with the density of somatostatin-specific receptors, especially SSR type 2, could in a more exact way approve or deny the antitumor effect of octreotide notified in this study.
Octreotide is recommended as a powerful additional therapy, together with surgical, irradiation and high-dose chemotherapy, at the moment of the diagnosis of a primary high-risk medulloblastoma, and especially in case of its recurrence or a metastasis.
